Introduction
Osteoarthritis (OA) is a slowly progressive degenerative joint disease that is traditionally associated with radiographic signs of joint space narrowing, osteophyte formation, and subchondral sclerosis. Its main clinical symptoms are variable joint pain and stiffness, and occasional effusion. However, radiographic signs and clinical symptoms only develop in late-stage OA when significant joint damage has already occurred 1e4 . Development of disease modifying treatment modalities for OA is challenging; lack of in-depth understanding of disease pathogenesis, the slowly progressive character of OA, the insensitivity of monitoring methods, and the limited relation between pain, disability and structural changes, still necessitate long and largescale therapeutic trials. Therefore, current treatment strategies are limited and mainly based on analgesics and, eventually, surgical procedures.
Biomarkers are defined as characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic interventions 5 . A lot of effort has been put into development of biochemical markers that can aid diagnosing early-stage OA, predicting OA progression, and assessing therapeutic response.
The availability of such biochemical markers could dramatically improve diagnosis and treatment of OA. With this in mind, numerous research groups study a plethora of potential biochemical markers of joint metabolism and/or disease: molecules or molecular fragments that are released into biological fluids from extracellular matrix turnover and/or cellular metabolism of articular cartilage, subchondral bone and synovial tissue. Although the rationale behind biochemical markers seems so clear, breakthroughs in the biochemical marker field are limited so far and some authors now even doubt future applicability of biochemical markers for OA 6 . In 2006, Bauer et al. proposed the "BIPED" biomarker classification, in which the acronym "BIPED" stands for Burden of disease, Investigative, Prognostic, Efficacy of intervention, and Diagnostic 7 .
According to this classification, each biochemical marker can be classified to one or more of these categories. However, since its introduction, the classification has hardly been used. This is unfortunate, because widespread use of a proper classification would enhance clear communication and contribute to organization of current knowledge.
Therefore, this systematic review aims to assess the current status of commercially available biochemical markers for each of the "BIPED" classification categories. This initiative might encourage future widespread use of this classification. Additionally, by evaluating the thus far performed study designs and their results, it contributes to development of directions for future study designs.
Method
Three electronic databases were searched for relevant publications: PubMed, Scopus, and EMBASE. Key words in these searches were as follows: OA/osteoarthrosis/arthrosis, knee/hip, biomarkers/ biological markers/biochemical markers, and blood/serum/plasma/ urine. The search was limited to urinary and blood biochemical markers, since these are the most relevant biochemical markers for clinical practice. Also, the search was limited to primary knee and hip-OA, both frequent and invalidating forms of peripheral OA.
Selection of publications was performed stepwise. First of all, publications needed to be published in English, between 1st January 1997 and 1st May 2009, and contain original data. Then, one of the authors (WvS) identified relevant publications by screening titles and abstracts for publications on human subjects, primary knee and/or hip-OA (publications on explicit secondary OA, e.g., after cruciate ligament rupture, were excluded), blood or urinary biochemical marker concentrations, and biochemical markers of matrix metabolism. Identified publications were then completely read and evaluated for biochemical marker application according to any of the "BIPED" categories.
Individual analyses of biochemical marker performance within any of the "BIPED" categories were extracted from these publications. Thus, each publication could contain one or more of these analyses; e.g., for knee and/or hip-OA, for several biochemical markers, for several "BIPED" categories, and/or for several parameters within a "BIPED" category. Analyses of biochemical marker performance within the "BIPED" categories were scored as follows:
e Diagnostic: biochemical marker concentrations were statistically significantly different between patient and control populations (tabulated as 'þ'); e Burden of disease: biochemical marker concentrations differed statistically significantly between patient populations with different disease severity (discrete; tabulated as 'þ') or biochemical marker concentrations correlated significantly with parameters of disease severity (continuous; tabulated as 'þþ'); e Prognostic: biochemical marker concentrations differed statistically significantly between patient populations with progressive and non-progressive OA or between participants that did and did not develop incident OA during follow-up (discrete; both tabulated as 'þ'), or biochemical marker concentrations correlated significantly with progression of parameters of disease severity during follow-up (continuous; tabulated as 'þþ'); e Efficacy of intervention: biochemical marker concentrations differed statistically significantly between patient populations with and without treatment, or before and after treatment within patients (discrete; both tabulated as 'þ'). Importantly, publications on the biochemical marker concentrations after arthroplastic surgery were not included. e Investigative: biochemical markers in this category fell outside the scope of this review and were therefore not included.
Note that results that were not statistically significant were scored 'À' for respective "BIPED" categories. Significance was strictly defined as P < 0.05. Remarkably, several publications handled this definition with more flexibility when discussing their results, and as such suggest relevant differences that are not supported by their statistical data evaluation. For all analyses, it was attempted to tabulate the most relevant score. For example, when a statistically significant difference of biochemical marker concentrations between patients and controls became insignificant after adjusting for age and body mass index (BMI), the diagnostic capability of that biochemical marker was scored negative (i.e., 'À'). Likewise, when biochemical marker concentrations correlated significantly with disease parameters in univariate analyses but not anymore after multivariate analyses, the correlation was scored negative. All analyses of biochemical marker performance in relation to the "BIPED" categories were summarized in separate tables for knee and hip-OA (Tables 1 and 2, Supplementary Tables). Each table  consists of six panels; cartilage synthesis, cartilage degradation, bone synthesis, bone degradation, synovial tissue synthesis/ anabolic activity, and synovial tissue degradation/catabolic activity, primarily based on the review by Garnero et al. 8 . It is important to realize that this categorization is mainly hypothetical and that actually little is known about the systemic origin and metabolism of many of the biochemical markers. In most cases the exact nature of the molecular entities being measured is open to debate. General study characteristics are depicted in the left part of the tables. General scores for biochemical marker performance within "BIPED" categories (À/þ) are depicted in the middle part of the tables. When a biochemical marker scored 'þ' or 'þþ' for any of the individual analyses within one "BIPED" category, the general score for that "BIPED" category is 'þ'. When a biochemical marker scored 'À' for all individual analyses within a "BIPED" category, the general score for that "BIPED" category was 'À'. When no individual analyses were applicable to one of the "BIPED" categories, that "BIPED" category was not scored. These general "BIPED" scores were considered most representative of biochemical marker performance, and were used for calculations afterwards and referred to in the Results section. To allow a more detailed review of the background of the general "BIPED" scores, the aforementioned individual analyses from the original publications and their outcomes are also provided, in the right part of the tables. Finally, the number of general "BIPED" scores per biochemical marker and per category of biochemical markers and the percentage of positive scores were summarized in Table I . Data extraction and tabulation were performed by one author (WvS) and verified by at least one of the other authors (FL, JDG, WL). Different interpretations between authors were discussed until consensus was achieved.
Results

General
The database searches resulted in retrieval of 899 publications. Figure 1 describes the subsequent selection of 84 relevant publications.
A total of 428 general "BIPED" scores were extracted from these publications. Of these scores, 331 (77%) concerned biochemical marker performance in knee-OA, while 97 (23%) concerned hip-OA.
Biochemical markers of collagen metabolism gained most attention. Of all 26 identified biochemical markers, 15 concerned collagen metabolism. Eight biochemical markers concerned collagen type II degradation (CTX-II, HELIX-II, C2C, Coll 2-1, Coll 2-1 NO (2), TIINE) and synthesis (PIIANP, PIICP), five concerned collagen type I degradation (NTX-I, CTX-I, ICTP) and synthesis (PICP, PINP), one concerned collagen type I and II degradation (C1, 2C) and one concerned collagen type III synthesis (PIIINP). Among these biochemical markers, urinary CTX-II (uCTX-II) was investigated most extensively; 66 times in total. , and pentosidine were the other biochemical markers that are considered biochemical markers of matrix metabolism. Of these, serum COMP (sCOMP) and sHA were scored relatively often in comparison with the other biochemical markers: 57 and 45 times, respectively. All other biomarkers were scored less frequently; most were scored one or two times per "BIPED" category. This limited number of scores for the majority of individual biochemical markers necessitated analysis per biochemical marker category (synthesis/degradation, articular cartilage/subchondral bone/synovial tissue) for comparisons instead of individual biochemical markers.
Information on the molecular basis of most biochemical markers is described in the comprehensive review by Garnero et .
Diagnostic
The diagnostic applicability of serum and urinary biochemical markers was scored 76 times (66 times for knee-OA and 10 times for hip-OA) (Table I) . Based on the number of studies, it was clear that cartilage degradation is considered by many, the main and central event in OA; biochemical markers of cartilage degradation had been extensively investigated for their diagnostic applicability in comparison with other biochemical marker categories. This category performed quite adequately: for knee-OA, 26 of the 34 investigations (76%) were scored positive. For hip-OA, all nine reports (100%) scored positive. Although biochemical markers of synovial tissue degradation received less attention (11 scores for knee-OA, no scores for hip-OA), they appeared to perform considerably well: nine out of the 11 scores (82%) were positive.
Biochemical markers of matrix synthesis were studied less than those of matrix degradation in knee-OA, and not at all in hip-OA. On the contrary, data on biochemical markers of bone degradation and bone synthesis for diagnostic purposes were reported more evenly; 10 and eight reports, respectively. Explanations for this could be the interest in the process of subchondral sclerosis and/or the availability of markers that were originally developed for bone diseases such as osteoporosis. Biochemical markers of bone synthesis and degradation performed somewhat less in diagnosing knee-OA than biochemical markers of cartilage and synovial tissue metabolism; five out of the nine reports (56%) on biochemical markers of bone degradation, and three out of the eight reports (38%) on biochemical markers of bone synthesis were scored positive.
Burden of disease
In total, serum and urinary biochemical marker concentrations were investigated for correlations with parameters of burden of disease 197 times (197 general "BIPED" scores). Again, biochemical markers of matrix degradation were investigated more frequently and performed better than those of matrix synthesis and biochemical markers of bone metabolism performed less adequately than those of cartilage metabolism. General performance was somewhat lower than in the Diagnostic category. Biochemical markers of cartilage degradation showed a significant correlation with structural and clinical parameters of burden of disease in 35 of the 70 reports (50%) and 12 of the 26 reports (46%), respectively. Biochemical markers of cartilage synthesis only correlated significantly with structural parameters of burden of disease in four of 13 reports (31%) and clinical parameters in one of five reports (20%). Biochemical markers of bone degradation scored positive for relations with structural parameters of burden of disease in nine out of 24 scores (38%), but did not score positive for correlations with clinical parameters in any of nine scores (0%). Biochemical markers of bone synthesis performed comparably disappointingly; significant correlations with structural parameters of burden of disease in two out of 16 publications (13%), and with clinical parameters of disease in two out of four publications (50%).
Also biochemical markers of synovial tissue metabolism/activity performed less in the Burden of disease category than in the Diagnostic category. For hip-OA, none of the five reports (0%) on biochemical markers of synovial tissue metabolism and structural and clinical parameters of burden of disease scored positive. For biochemical markers of synovial tissue degradation in knee-OA, six out of 15 scores (40%) and four out of eight scores (50%) were positive for the relations with structural and clinical disease parameters, respectively. The serum biochemical marker of synovial tissue synthesis PIIINP was only scored twice.
The relative number of reports showing significant relations between biochemical markers of cartilage metabolism and parameters of burden of disease did not differ between structural and clinical parameters of burden of disease. The same applies to biochemical markers of synovial tissue degradation and synthesis. For biochemical markers of bone metabolism this is less clear (see Table I ).
Prognostic
Prognostic performance of biochemical markers in knee and hip-OA was scored 126 times in total. Sixty-eight of these scores concerned biochemical markers of cartilage degradation. Biochemical markers of cartilage degradation performed not so well in predicting OA course; 25 out of 48 scores (52%) and seven out of 20 scores (35%) were positive for relations between them and structural and clinical OA progression, respectively. Biochemical markers of cartilage synthesis were only investigated on their relation with disease course for knee-OA. One out of seven scores (14%) was positive for the relation between them and structural progression, while one out of three scores (33%) was positive for their relation with clinical progression. Biochemical markers of bone metabolism had been moderately investigated for their prognostic applicability in knee and hip-OA; 36 scores. Few publications reported positively on predicting structural progression. Their performance in predicting clinical progression was even worse: only one out of 12 scores (8%) was positive for the relations between clinical progression of knee and hip-OA and biochemical markers of bone metabolism.
Although biochemical markers of synovial tissue degradation were scored only 11 times, they performed quite well: five out of six scores (83%) and one out of one score (100%) were positive for their relationship with structural progression of knee and hip-OA, respectively. The same accounted for clinical progression: one out of three scores (33%) showed significant relations with clinical progression of knee-OA, and one out of one (100%) showed this for hip-OA. The only scores for performance of biochemical markers of synovial tissue synthesis showed that sPIIINP concentrations did not predict structural or clinical progression of hip-OA in a multivariate analysis.
Efficacy of intervention
Twenty-nine scores for the relationships between biochemical marker concentrations and interventions were evaluated. Seventeen reports on the relationship between interventions and biochemical markers of cartilage degradation were found. Among the biochemical markers of cartilage degradation, uCTX-II was the most frequently studied biochemical marker. Four out of five scores (80%) were positive for the change of uCTX-II concentration after intervention. The publication not showing significant changes of uCTX-II concentrations was on intervention with chondroitin sulphate and showed minimal or insignificant changes of clinical primary and secondary outcomes as well 16 . Another publication failed to show efficacy of oral risedronate on radiographic progression, but showed significant and dose-dependent changes of uCTX-II concentrations 17 . Other biochemical marker categories were scored less frequently and, surprisingly, biochemical markers of synovial tissue synthesis were not scored at all.
Discussion
This review provides an overview of publications on biochemical marker performance in primary knee and hip-OA and categorizes their data according to the "BIPED" classification. It is obvious that biochemical markers of matrix degradation, and specifically cartilage degradation, received much attention in comparison with other biochemical marker categories. Biochemical markers of matrix degradation performed better than those of matrix synthesis. Biochemical markers of matrix synthesis are probably most useful in combination with those of matrix degradation, as has been demonstrated before 3,18e20 . Biochemical markers of bone metabolism have been investigated to some extent, but their performance was relatively disappointing. The contribution of subchondral bone to systemic biochemical marker concentrations may be obscured by the turnover of the complete skeleton. Biochemical markers of synovial tissue metabolism have not (yet) been investigated extensively, but available data looked promising, suggesting involvement of synovial tissue in OA 21 . It is also clear that biochemical markers have been more extensively investigated in knee-OA than in hip-OA. Although complicated by this uneven distribution, there is no obvious evidence that biochemical marker performance is lower in hip-OA.
Overall, uCTX-II and sCOMP had the best performance of all currently available commercial biochemical markers; they were investigated most frequently and broadly, and scored in the higher ranges of scores for most "BIPED" categories. However, this review does not intend to suggest which of the investigated biochemical markers intrinsically performs best, since the actual performance of the majority of other serum and urinary biochemical markers cannot be adequately evaluated as they were not that extensively investigated as uCTX-II and sCOMP; most showed a maximum of three general "BIPED" scores per "BIPED" category. Also the observed heterogeneity among publications is a major complicating factor in this respect. The majority of publications on less frequently studied biochemical markers had an exploratory character with small-sized populations and/or applied a caseecontrol design. Finally, comparison between biochemical markers is likely to be complicated by publication bias; negative results will not always be communicated. Especially in the Efficacy of intervention category this could be a major factor.
No consistent differences were observed between study designs of those studies performing well for a certain biochemical marker and those that did not. This was again complicated by the uneven distribution of "BIPED" scores among biochemical markers. Among the studies on more extensively investigated biochemical markers, those on sCOMP seemed to perform somewhat less than those on uCTX-II within most "BIPED" categories. This could be a non-relevant difference or may be due to selection bias in the performed database search strategy, but may also be due to differences in cohort and study design. Patient and control populations of the publications on uCTX-II were frequently obtained from population-based cohorts and clinical trials, while populations of publications on sCOMP were frequently less wellcharacterized. When participants are selected on tightly defined criteria, populations can be expected to be more homogeneous and as such enable biochemical marker concentrations to show more clear differences and/or correlations. Also, more publications on uCTX-II paid special attention to sample collection methods (e.g., fasting, second morning void urine) in comparison with publications on sCOMP. It is suggested that standardization of sample collection may improve biochemical marker performance, since diurnal rhythms and influences of exercise have been described for several biochemical markers 22e26 . Careful cohort and study design could therefore explain part of the somewhat better performance of uCTX-II.
The majority of scores for the cross-sectional and longitudinal relationships between biochemical markers and disease parameters concerned structural parameters rather than clinical parameters. Structural disease was mainly defined radiographically. However, radiography is especially suited for visualization of bone structures, while it can only indirectly visualize cartilage and cannot visualize synovial tissue. Therefore, correlation of biochemical markers of synovial tissue metabolism with radiographic parameters can theoretically be expected to be minimal. Additional observation of structural parameters by ultrasonography, magnetic resonance imaging (MRI) or arthroscopy enables more direct visualization of cartilage and synovial tissue and could therefore lead to better and more representative correlations. 29 . These participants complained of chronic knee pain and/or other knee limitations but did not always have radiographically detectable knee-OA. MRI had been used to compose a whole organ MRI score that is composed of cartilage, subchondral bone, synovial tissue and periarticular tissue parameters in knee-OA 31 . Another feature that was observed by MRI and had been correlated to biochemical marker concentrations is the presence of bone marrow lesions in knee-OA 32e34 . In the publications that were included in this review, publications on sCOMP reported more heterogeneous disease parameters than those on uCTX-II, and included ultrasonographic, MRI and scintigraphic parameters. In contrast to the suggested above, our scoring method was not clearly able to show an additive value of these alternative approaches in supporting the applicability of sCOMP in OA. This review shows that there is a lack of consistent evidence for the vast majority of commercially available biochemical markers. This lack of interest for these less frequently studied biochemical markers is not necessarily supported by publications showing limited applicability. Additional investigation of these biochemical markers in large-scale, cohort studies is crucial to increase our knowledge about the applicability of these biochemical markers and aid to our understanding of OA pathogenesis. Most biochemical markers are still in an explorative stage and publication bias is therefore undesirable and should be prevented. Also, this review shows that our knowledge of applicability of biochemical markers in hip-OA is limited in comparison with knee-OA. Additional investigation on hip-OA, and other types of OA, is therefore encouraged.
Little is known about molecular validity, systemic origin and metabolism of the majority of biochemical markers, and with that implications of measured biochemical marker concentrations are still open to debate. For example, Eyre et al. debated presence of the HELIX-II epitope on collagen type II and suggested its presence on collagen type III degradation products instead 15 . This lack of knowledge of the molecular validity of biochemical markers and systemic biochemical marker origins and metabolism forms a major barrier in performing and interpreting clinical biochemical marker studies. For example, Otterness et al. detected an unexpected increase of uTIINE concentrations in doxycyclinetreated knee-OA patients and could only speculate about doxycycline-induced changes of sTIINE metabolism 35 . As such, there is an urgent need for investigation of the many unknowns about sources and systemic metabolism of biochemical markers and correlation with specific aspects of OA. Incorporation of methodologies that were originally developed and demanded by regulatory authorities to study pharmacokinetics of drugs (i.e., absorption, distribution, metabolism and excretion) in biochemical marker characterization would be useful in this respect. Knowledge of these aspects of biochemical markers would contribute to adequate set-up of clinical studies and proper interpretation of results thereof.
Comparison of biochemical marker performance is complicated by the uneven distribution of biochemical marker performance scores and heterogenic study design. Also, this heterogeneity hampers pooling of data. International standards of study design would increase homogeneity of data, and dramatically increase quality and efficacy of biochemical marker investigation and thereby contribute to progression of the biochemical marker field.
Conclusion
None of the current biochemical markers is sufficiently discriminating to aid to diagnosis and prognosis of OA in individual or limited numbers of patients, or performs so consistently that it could function as an outcome in clinical trials. Future research should focus on molecular validation, origins and metabolism of biochemical markers as well as on broad spectrum biochemical marker analysis in well-defined populations, with protocolized sample collection. Most importantly, more research should be aimed at clarifying the many unknowns about sources and systemic metabolism of biomarkers and correlation with specific aspects of the pathology, to bring the biomarker field significant steps forward.
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